Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06273098 Withdrawn - Clinical trials for Urinary Tract Infections

School-Based Bladder Health Intervention

Start date: January 1, 2028
Phase: N/A
Study type: Interventional

The aim of this study is to promote healthy bladder behaviors among school children. We hypothesize that a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies can promote healthy bladder behaviors among school children.

NCT ID: NCT06259266 Withdrawn - Clinical trials for Chronic Renal Failure

Catheter Dysfunction Rate in Patients Undergoing Kidney Replacement Therapy. Evaluation of the Safety and Efficacy of Anti-reflux Valves Without Heparin Lock Solution

DUKE
Start date: December 2013
Phase: N/A
Study type: Interventional

Catheter dysfunction and infections are the most common complications observed among patients with dialysis catheters for long-term dialysis ( CDLD ) . They are causing a worsening of the morbidity and mortality of patients , loss of quality of renal replacement therapy , a reduction in the duration of catheterization , as well as increased spending related to health care. The use of anti- reflux ( Tego ® , ICU Medical , USA, distributed by the Laboratory Hemotech , FRANCE ) valves reduces the rate of dysfunction and infections CDLD( catheters for long-term dialysis ). Unpublished preliminary data suggest that these valves allow parallel use of interdialytic saline locks without increasing the risk of dysfunction. This strategy would therefore achieve significant savings usual interdialytic CDLD( catheters for long-term dialysis )locks ( including heparin) whose use is not devoid of potentially serious adverse events and whose health care costs have increased dramatically in recent years . Moreover, this would also produce savings in fibrinolytic treatment. A randomized controlled trial is needed to assess the effectiveness of TEGO ® valves in combination with saline locks on the risk of dysfunction CDLD(catheters for long-term dialysis ) .

NCT ID: NCT06133010 Withdrawn - Clinical trials for Cytomegalovirus Infection

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Start date: February 8, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of pre-transplant mRNA-1647 on post-transplant cytomegalovirus (CMV) virologic outcomes, anti-CMV antiviral use, and clinical outcomes in CMV-seropositive and CMV-seronegative liver transplant candidates who receive transplants and to assess the safety, reactogenicity, and immunogenicity of mRNA-1647 in all participants.

NCT ID: NCT05769569 Withdrawn - HIV-1-infection Clinical Trials

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

RV582
Start date: September 1, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, randomized, open-label trial to investigate the safety of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-Bavarian Nordic (BN)-HIV and A244d11gp120/ALFQ vaccination, and the impact on time to sustained viral rebound of ≥1000 copies/mL for 4 consecutive weeks during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who initiated antiretroviral therapy (ART) during acute HIV-1 infection (AHI).

NCT ID: NCT05700630 Withdrawn - HIV-1-infection Clinical Trials

Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

Start date: July 15, 2024
Phase: Phase 1
Study type: Interventional

This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy (ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept of "Kick and Kill".

NCT ID: NCT05692986 Withdrawn - Clinical trials for Preventative Laparoscopic Hysterectomy

Chlorhexidine vs Povidone Iodine Vaginal Prep in Decreasing Postoperative Infection in Total Laparoscopic Hysterectomy

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

This is a randomized control trial which will randomize patients who will be undergoing laparoscopic (conventional or robotic assisted) total hysterectomy to vaginal prep with 4% chlorhexidine gluconate vs 10% povidone iodine. There is paucity of information regarding the superiority of one over the other.

NCT ID: NCT05639504 Withdrawn - Sepsis Clinical Trials

Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)

Start date: December 2022
Phase:
Study type: Observational

This study aims to evaluate the diagnostic and prognostic performance of a novel mRNA diagnostic/prognostic classifier (interprets the expression of 29 host response mRNA biomarkers) from whole blood in adult patients presenting to emergency departments (ED) with suspected infection.

NCT ID: NCT05589844 Withdrawn - Clinical trials for Hematopoietic and Lymphoid System Neoplasm

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Start date: March 2023
Phase: Phase 1
Study type: Interventional

This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic hematopoietic stem cell transplant. CMV is an opportunistic infection that can occur or reactivate after allogeneic hematopoietic stem cell transplant as a result of immunosuppression. The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules called cytokines, as well as CMV proteins. Introducing these dendritic cells to the patients immune system may activate an immune response to CMV, protecting against infection or reactivation.

NCT ID: NCT05399615 Withdrawn - Infectious Disease Clinical Trials

Detection of Bacterial and Viral Pathogens Infection Among Hospitalized Patients Feasibility Study

Infection
Start date: December 30, 2022
Phase: N/A
Study type: Interventional

Detection of bacterial and viral pathogens infection among hospitalized patients using breath analysis - feasibility study.

NCT ID: NCT05269134 Withdrawn - Clinical trials for Prosthetic Joint Infection

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

ACTIVE2
Start date: March 27, 2023
Phase: Phase 2
Study type: Interventional

This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections.